impact of different platelet glycoprotein iib/iiia receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : do ...  the platelet glycoprotein iib/iiia receptor inhibitor  xxxd53xxx , a monoclonal antibody, has been shown to improve early and late outcomes among diabetic patients undergoing percutaneous coronary intervention (pci). it is unknown whether small-molecule agents confer similar benefits.